Skip to Content

Capecitabine SUN

Active Substance: capecitabine
Common Name: capecitabine
ATC Code: L01BC06
Marketing Authorisation Holder: Sun Pharmaceutical Industries Europe B.V.
Active Substance: capecitabine
Status: Withdrawn
Authorisation Date: 2013-06-21
Therapeutic Area: Colorectal Neoplasms Colonic Neoplasms Stomach Neoplasms Breast Neoplasms
Pharmacotherapeutic Group: Capecitabine

Therapeutic Indication

Capecitabine is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.

Capecitabine is indicated for the treatment of metastatic colorectal cancer.

Capecitabine is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.

Capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

The marketing authorisation for Capecitabine SUN has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide